Cargando…
MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock
BACKGROUND: TLR-2 is expressed on the surface of leucocytes, lung and liver tissue and initiates the activation of immune response after interaction with components of the bacterial cell wall. In this experiment we investigated whether immunostimulation with TLR-2 agonists under conditions of steril...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640975/ https://www.ncbi.nlm.nih.gov/pubmed/23587413 http://dx.doi.org/10.1186/1476-9255-10-17 |
_version_ | 1782267958338256896 |
---|---|
author | Pfeifer, Roman Tschernig, Thomas Lichte, Philipp Dombroski, Derek Kobbe, Philipp Pape, Hans-Christoph |
author_facet | Pfeifer, Roman Tschernig, Thomas Lichte, Philipp Dombroski, Derek Kobbe, Philipp Pape, Hans-Christoph |
author_sort | Pfeifer, Roman |
collection | PubMed |
description | BACKGROUND: TLR-2 is expressed on the surface of leucocytes, lung and liver tissue and initiates the activation of immune response after interaction with components of the bacterial cell wall. In this experiment we investigated whether immunostimulation with TLR-2 agonists under conditions of sterile inflammation (hemorrhagic shock (HS)) may affect the immune response and remote organ inflammation. METHODS: Male C57/BL6 mice were subjected to standardized pressure-controlled HS (MAP of 35 mmHg for 90 minutes). The TLR-2 agonist macrophage-activated lipopeptide-2 (MALP-2) was administered (i.p.) either 12 hours prior to the induction of HS (Group MALP PT) or after the hypotensive period (90 minutes) (Group MALP T). After six hours, plasma cytokine levels (IL-6, KC, IL-10, and MCP-1) and lung and liver MPO activity were assessed. RESULTS: Pre-treatment with MALP-2 resulted in a significant attenuation of the systemic pro-inflammatory (IL-6) response (MALP PT: 0.83±0.2 ng/ml vs. MALP T: 1.7±0.09 ng/ml) (p<0.05). In comparison to the liver MPO activity, lung MPO levels in in group MALP PT did not show differences to levels measured in MALP T mice (1.200±200 ng/mg vs. 1.800±200 ng/mg). CONCLUSIONS: After initial inflammation, MALP-2 pre-treatment was associated with attenuated systemic immune response after sterile stimulus. The TLR-2 agonist appears to affect sterile inflammation pathways. The exact mechanisms should be studied further to better understand these affects. |
format | Online Article Text |
id | pubmed-3640975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36409752013-05-02 MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock Pfeifer, Roman Tschernig, Thomas Lichte, Philipp Dombroski, Derek Kobbe, Philipp Pape, Hans-Christoph J Inflamm (Lond) Research BACKGROUND: TLR-2 is expressed on the surface of leucocytes, lung and liver tissue and initiates the activation of immune response after interaction with components of the bacterial cell wall. In this experiment we investigated whether immunostimulation with TLR-2 agonists under conditions of sterile inflammation (hemorrhagic shock (HS)) may affect the immune response and remote organ inflammation. METHODS: Male C57/BL6 mice were subjected to standardized pressure-controlled HS (MAP of 35 mmHg for 90 minutes). The TLR-2 agonist macrophage-activated lipopeptide-2 (MALP-2) was administered (i.p.) either 12 hours prior to the induction of HS (Group MALP PT) or after the hypotensive period (90 minutes) (Group MALP T). After six hours, plasma cytokine levels (IL-6, KC, IL-10, and MCP-1) and lung and liver MPO activity were assessed. RESULTS: Pre-treatment with MALP-2 resulted in a significant attenuation of the systemic pro-inflammatory (IL-6) response (MALP PT: 0.83±0.2 ng/ml vs. MALP T: 1.7±0.09 ng/ml) (p<0.05). In comparison to the liver MPO activity, lung MPO levels in in group MALP PT did not show differences to levels measured in MALP T mice (1.200±200 ng/mg vs. 1.800±200 ng/mg). CONCLUSIONS: After initial inflammation, MALP-2 pre-treatment was associated with attenuated systemic immune response after sterile stimulus. The TLR-2 agonist appears to affect sterile inflammation pathways. The exact mechanisms should be studied further to better understand these affects. BioMed Central 2013-04-12 /pmc/articles/PMC3640975/ /pubmed/23587413 http://dx.doi.org/10.1186/1476-9255-10-17 Text en Copyright © 2013 Pfeifer et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Pfeifer, Roman Tschernig, Thomas Lichte, Philipp Dombroski, Derek Kobbe, Philipp Pape, Hans-Christoph MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock |
title | MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock |
title_full | MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock |
title_fullStr | MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock |
title_full_unstemmed | MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock |
title_short | MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock |
title_sort | malp-2 pre-treatment modulates systemic inflammation in hemorrhagic shock |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640975/ https://www.ncbi.nlm.nih.gov/pubmed/23587413 http://dx.doi.org/10.1186/1476-9255-10-17 |
work_keys_str_mv | AT pfeiferroman malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock AT tschernigthomas malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock AT lichtephilipp malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock AT dombroskiderek malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock AT kobbephilipp malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock AT papehanschristoph malp2pretreatmentmodulatessystemicinflammationinhemorrhagicshock |